New topics in familial prion diseases

Abstract

Major advances have been made in the understanding of the molecular basis of phenotypic variability in human prion diseases over the last few years. Strong evidence indicates that a complex interaction between specific mutations and the polymorphic codon 129 of the prion protein gene ( PRNP) underlies the genetic control of phenotypic expression in familial human prion diseases. Fatal familial insomnia (FFI) and a subtype of familial CJD (CJD 178), two prion diseases with different clinico-pathological features, the same mutation at codon 178 of PRNPbut a different amino acid at codon 129 of the mutant PRNPallele, represent the best characterized example of this complex interplay between the PRNPgenotype and phenotypic variability. Protein studies have subsequently shown that the different genotype of the mutant allele in FFI and CJD 178results in the formation of two different protease-resistant prion proteins (PrP res) which differ in size and glycosylation. These biochemical characteristics of PrP resas well as differences among distinct brain regions in the timing and rate of PrP resdeposition and in the vulnerability to PrP resalso appear to be major determinants of phenotypic expression in human prion diseases.